

[â—€è¿”å›](./home.md)

# å“Œå¼‚ä¸™é…¯ (Isopropylphenidate)

<mark> ç¿»è¯‘å¾—ä¸é”™ï¼Œ è¿æ¥å¤„ç†çš„ä¹Ÿåˆ°ä½ï¼Œä½†æ˜¯æœ‰äº›ä¸œè¥¿ä¸ç¬¦åˆç¿»è¯‘è§„èŒƒ</mark>

| å“Œå¼‚ä¸™é…¯ (Isopropylphenidate) | |
| --- | --- |
| [![Isopropylphenidate.svg](../æ–‡ä»¶/Isopropylphenidate.svg)](../æ–‡ä»¶/Isopropylphenidate.svg) | |
| åŒ–å­¦å‘½å | |
| å¸¸ç”¨å | *Isopropylphenidate, IPH, IPPH* |
| å–ä»£åç§° | *Isopropylphenidate* |
| ç³»ç»Ÿå | *Propan\-2\-yl 2\-phenyl\-2\-(piperidin\-2\-yl)acetate* |
| ç±»åˆ«æˆå‘˜ | |
| ç²¾ç¥è¯æ•ˆåˆ†ç±» | *[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")* |
| åŒ–å­¦åˆ†ç±» | *[è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Phenidate")* |
| [ç»™è¯é€”å¾„](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| - **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚ <br>   <br>    | â‡£ [å£æœ](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") |
| --- | --- |
| [ç»™è¯å‰‚é‡](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") | |
| [é˜ˆå€¼](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 2 mg |
| [è½»å¾®](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 5 \- 15 mg |
| [ä¸­ç­‰](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 15 \- 25 mg |
| [å¼ºçƒˆ](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 25 \- 45 mg |
| [ä¸¥é‡](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 45 mg \+ |
| [è¯æ•ˆæ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | |
| [æ€»æ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 3\.5 \- 6 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 10 \- 30 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 20 \- 40 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1\.5 \- 2\.5 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 \- 2 å°æ—¶ |
| â‡£ [é¼»å¸](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| [ç»™è¯å‰‚é‡](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage") | |
| [é˜ˆå€¼](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 2 mg |
| [è½»å¾®](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 5 \- 10 mg |
| [ä¸­ç­‰](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 10 \- 20 mg |
| [å¼ºçƒˆ](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 20 \- 35 mg |
| [ä¸¥é‡](../æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 35 mg \+ |
| [è¯æ•ˆæ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | |
| [æ€»æ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 2\.5 \- 4 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 2 \- 5 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 10 \- 30 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 \- 2 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 \- 1\.5 å°æ—¶ |
| <br>   <br>   <br>   <br>   <br>    - **[å…è´£å£°æ˜](../æ–‡æ¡£/å…³äºFreeODwiki.md "Disclaimer"):** æœ¬ç«™çš„[ç»™è¯å‰‚é‡](../æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[èµ„æº](../å…³äºæœ¬ç«™/home.md "Network")ï¼Œä»…ä¾›æ•™è‚²ç”¨é€”ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ | |
| [è¯ç‰©è”ç”¨](#dangerous_interactions) | |
| [é…’ç²¾](../è¯ç‰©/é…’ç²¾.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [MXE](../è¯ç‰©/MXE.md) | ğŸ’” è”ç”¨å±é™© |
| [è§£ç¦»å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md) | ğŸ’” è”ç”¨å±é™© |
| [å³ç¾æ²™èŠ¬](../è¯ç‰©/å³ç¾æ²™èŠ¬.md) | ğŸ’” è”ç”¨å±é™© |
| [MDMA](../è¯ç‰©/MDMA.md) | ğŸ’” è”ç”¨å±é™© |
| [å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) | ğŸ’” è”ç”¨å±é™© |
| [25x-NBOMe](../è¯ç‰©/25x-NBOMe.md) | ğŸ’” è”ç”¨å±é™© |
| [25x-NBOH](../è¯ç‰©/25x-NBOH.md) | ğŸ’” è”ç”¨å±é™© |
| [æ›²é©¬å¤š](../è¯ç‰©/æ›²é©¬å¤š.md) | ğŸ’” è”ç”¨å±é™© |
| [MAOIs](../è¯ç‰©/MAOIs.md) | ğŸ’” è”ç”¨å±é™© |

**å“Œå¼‚ä¸™é…¯**ï¼ˆIsopropylphenidateï¼Œä¹Ÿç§°ä¸º **IPH**ã€**IPPH**ã€**IPD** å’Œ **IPPD**ï¼‰æ˜¯ä¸€ç§[è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Phenidate")ä¸­è¾ƒå°‘ä¸ºäººçŸ¥çš„æ–°å‹[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ã€‚å®ƒæ˜¯å¹¿æ³›å¤„æ–¹çš„ ADHD è¯ç‰©[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")çš„ç»“æ„ç±»ä¼¼ç‰©ã€‚å®ƒæ˜¯ä¸€ç§[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")\-[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor") (**NDRI**)ã€‚

äººä»¬å·²ç»ç ”ç©¶äº† IPPH æ›¿ä»£[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")ç”¨äºæ²»ç–— ADHD åŠç›¸å…³éšœç¢çš„æ½œåŠ›ã€‚[\[1\]](#cite_note-IPPHadhd-1) ä¸€é¡¹ç ”ç©¶å‘ç°ï¼Œå®ƒè¡¨ç°å‡ºä½œä¸º[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")\-[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor") (**NDRI**) çš„åŸºæœ¬æ´»æ€§ï¼Œä¸[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")å’Œ[ä¹™å“Œé†‹ç”²é…¯](../è¯ç‰©/EPH.md "Ethylphenidate")ä¸€æ ·ï¼Œå¯¹å¤šå·´èƒºè½¬è¿ä½“å…·æœ‰ç›¸å½“é«˜çš„äº²å’ŒåŠ›ï¼Œå¹¶å¯¹å…¶ç»†èƒå†æ‘„å–æœ‰å½±å“ã€‚ç„¶è€Œï¼Œå®ƒå¯¹[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")çš„å½±å“ç›¸å¯¹è¾ƒå°ï¼Œç†è®ºä¸Šè¿™æ„å‘³ç€å®ƒå¯èƒ½å…·æœ‰æ›´ç†æƒ³çš„å®‰å…¨æ€§å’Œæ¯’æ€§ç‰¹å¾ã€‚[\[2\]](#cite_note-IPPH-2)

[ä¸»è§‚æ•ˆåº”](../æ–‡æ¡£/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md "Subjective effects")åŒ…æ‹¬[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")ã€[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation enhancement")ã€[é£Ÿæ¬²æŠ‘åˆ¶](../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")å’Œ[æ¬£å¿«æ„Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Euphoria")ã€‚æ®æŠ¥é“ï¼Œå…¶è®¤çŸ¥å’Œèº«ä½“æ•ˆåº”ç±»ä¼¼äºå“Œç”²é…¯ï¼Œä½†[æ¬£å¿«](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Euphoria")çš„â€œå†²å‡»æ„Ÿâ€ï¼ˆrushï¼‰æˆåˆ†è¾ƒå°‘ï¼Œä¸”[è¯æ•ˆæ—¶é•¿](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration")æ›´é•¿ã€‚è¿™äº›ç‰¹æ€§ä½¿å¾—ä¸€äº›äººå£°ç§°å®ƒå¯èƒ½æ›´é€‚åˆç”¨ä½œå­¦ä¹ è¾…åŠ©æˆ–ç”Ÿäº§åŠ›å¢å¼ºå‰‚ã€‚[\[2\]](#cite_note-IPPH-2)[\[1\]](#cite_note-IPPHadhd-1)

IPPH åœ¨äººç±»ä¸­çš„[å¨±ä¹æ€§ç”¨è¯](../æ–‡æ¡£/å¨±ä¹æ€§ç”¨è¯.md "Recreational drug use")å†å²æçŸ­ã€‚å®ƒæœ€åˆæ˜¯åœ¨[ä¹™å“Œé†‹ç”²é…¯](../è¯ç‰©/EPH.md "Ethylphenidate")è¢«ç¦åå‘å¸ƒçš„ï¼ˆä¹™å“Œé†‹ç”²é…¯äº 2015 å¹´ 4 æœˆåœ¨ä¸´æ—¶ç¦ä»¤åè½¬ä¸ºæ°¸ä¹…å…¨é¢ç¦ä»¤è€Œåœ¨è‹±å›½å˜ä¸ºéæ³•ï¼‰ã€‚ä¸ä¹…ä¹‹åï¼Œå®ƒä½œä¸º[ç ”ç©¶ç”¨åŒ–å­¦å“](../æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")åœ¨åœ¨çº¿ç°è‰²å¸‚åœºä¸Šå‡ºå”®å¹¶åˆ†é”€å…¨çƒã€‚æˆªè‡³ 2022 å¹´ï¼ŒIPPH åœ¨ä¸–ç•Œè®¸å¤šåœ°æ–¹ä»ç„¶å¯ç”¨ä¸”æ³•å¾‹åœ°ä½æ¨¡ç³Šï¼Œå‡ ä¹å®Œå…¨ç”±åœ¨çº¿[ç ”ç©¶ç”¨åŒ–å­¦å“](../æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")ä¾›åº”å•†åˆ†é”€ã€‚

ç›®å½•
--------

* [1 åŒ–å­¦](#chemistry)
* [2 è¯ç†å­¦](#pharmacology)
* [3 ä¸»è§‚æ•ˆåº”](#subjective_effects)
    + [3\.1 **èº¯ä½“æ•ˆåº”**](#physical_effects)
    + [3\.2 **è¯æ•ˆæ®‹ä½™**](#after_effects)
    + [3\.3 **è®¤çŸ¥æ•ˆåº”**](#cognitive_effects)
    + [3\.4 ä½“éªŒæŠ¥å‘Š](#experience_reports)
* [4 æ¯’æ€§å’Œå±å®³æ½œåŠ›](#toxicity_and_harm_potential)
    + [4\.1 è€å—æ€§å’Œæˆç˜¾æ½œåŠ›](#tolerance_and_addiction_potential)
    + [4\.2 ç²¾ç¥ç—…](#psychosis)
    + [4\.3 å±é™©è¯ç‰©è”ç”¨](#dangerous_interactions)
* [5 æ³•å¾‹åœ°ä½](#legal_status)
* [6 å¦è§](#see_also)
* [7 å¤–éƒ¨é“¾æ¥](#external_links)
* [8 æ–‡çŒ®](#literature)
* [9 å‚è€ƒèµ„æ–™](#references)

åŒ–å­¦
---------

IPPH æ˜¯[å–ä»£è‹¯ä¹™èƒºç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md "Substituted phenethylamine")ã€[å–ä»£è‹¯ä¸™èƒºç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md "Amphetamine")å’Œ[è‹„åŸºå“Œå•¶ç±»ç‰©è´¨](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Phenidate")ç±»åˆ«çš„åˆæˆåˆ†å­ã€‚å®ƒåŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œå…·æœ‰ä¸€ä¸ªé€šè¿‡ä¹™åŸºé“¾ç»“åˆåˆ°æ°¨åŸº (NH2) çš„è‹¯ç¯ã€‚å®ƒåœ¨ç»“æ„ä¸Šç±»ä¼¼äº[è‹¯ä¸™èƒº](../è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")ï¼Œä½†åœ¨ RÎ± ä½ç½®æœ‰ä¸€ä¸ªå–ä»£åŸºï¼Œè¯¥å–ä»£åŸºå¹¶å…¥ä¸€ä¸ªä»¥è‹¯ä¹™èƒºé“¾æœ«ç«¯èƒºä¸ºç»ˆç‚¹çš„[å“Œå•¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md "Piperidine")ç¯ã€‚æ­¤å¤–ï¼Œå®ƒçš„åˆ†å­ç»“æ„ä¸­åŒ…å«ä¸€ä¸ªç»“åˆåˆ° RÎ² çš„ä¹™é…¸å¼‚ä¸™é…¯ï¼Œè¿™ä¸[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")æœ‰æ˜¾ç€ä¸åŒï¼Œåè€…åœ¨æ­¤ä½ç½®åŒ…å«ä¸€ä¸ªç”²åŸºã€‚

IPPH ä¸[ä¹™å“Œé†‹ç”²é…¯](../è¯ç‰©/EPH.md "Ethylphenidate")å’Œ[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")çš„ç»“æ„å·®å¼‚åœ¨äºå…¶ä¹™é…¸åŸºå›¢ä¸Šç¢³é“¾çš„é•¿åº¦ã€‚*Iso-* è¡¨ç¤ºä¾§é“¾ä¸ºä¸€ä¸ªç¢³åŸå­åˆ†æ”¯æˆä¸¤ä¸ªç»“åˆçš„ç”²åŸºï¼Œ*phen-* è¡¨ç¤ºè‹¯ç¯ï¼Œ*id-* æ˜¯å“Œå•¶ç¯çš„ç¼©å†™ï¼Œ*-ate* è¡¨ç¤ºä¹™é…¸åŸºå›¢ã€‚IPPH æ˜¯ä¸€ç§æ‰‹æ€§åŒ–åˆç‰©ï¼Œæ®è®°å½•å¯ä»¥ä»¥å¤–æ¶ˆæ—‹æ··åˆç‰©æˆ–ä¸“é—¨ä½œä¸ºå…¶å¯¹æ˜ å¼‚æ„ä½“ä¹‹ä¸€ç”Ÿäº§ã€‚[\[3\]](#cite_note-IPPHSynthesis-3)

è¯ç†å­¦
------------

å°šæœªè¿›è¡Œä½¿ç”¨ IPPH çš„æ­£å¼ä½“å†…äººä½“ç ”ç©¶ã€‚ç„¶è€Œï¼Œä½“å†…å¤§é¼ ç ”ç©¶å‘ç°äº†åˆºæ¿€ä½œç”¨ï¼›ä½“å¤–ç ”ç©¶åˆ†åˆ«è¯„ä¼°äº†å•èƒºè½¬è¿ä½“ç»“åˆäº²å’ŒåŠ›å’Œå„ç§æ°´è§£é…¶çš„äº²å’ŒåŠ›ã€‚[\[2\]](#cite_note-IPPH-2)[\[4\]](#cite_note-PhenidateHydrolysis-4) è¿™äº›ç ”ç©¶çš„ç»“æœè¡¨æ˜ï¼ŒIPPH å…·æœ‰ä¸å…¶æ¯ä½“åŒ–åˆç‰©[å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")éå¸¸ç›¸ä¼¼çš„è¯ç†å­¦ç‰¹æ€§ï¼Œä¸¤è€…ä¹‹é—´çš„æ˜¾è‘—å·®å¼‚åœ¨äº IPPH ä½œä¸º[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")çš„æ´»æ€§æ˜¾è‘—è¾ƒä½ï¼Œä»¥åŠä¸“é—¨è´Ÿè´£å°†è¿™ä¸¤ç§ç‰©è´¨æ°´è§£ä¸ºåˆ©ä»–æ—é…¸çš„ CES1 æ°´è§£é…¶å¯¹ IPPH çš„äº²å’ŒåŠ›æ¯”å¯¹å“Œç”²é…¯ä½ 8 å€ã€‚

è¿™äº›å·®å¼‚å¯¼è‡´è¯¥ç‰©è´¨åœ¨åŒç­‰æœ‰æ•ˆå‰‚é‡ä¸‹æ¯”å“Œç”²é…¯å…·æœ‰æ›´æ˜¾è‘—çš„[å¤šå·´èƒºèƒ½](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopaminergic")æ´»æ€§è€Œé[è‚¾ä¸Šè…ºç´ èƒ½](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")æ´»æ€§ï¼Œå¹¶ä¸”åœ¨ç»™å®šå‰‚é‡ä¸‹è¯¥ç‰©è´¨æ¯”å“Œç”²é…¯å…·æœ‰æ›´é•¿çš„æŒç»­æ—¶é—´å’Œæ›´å¼ºçš„æ•ˆåŠ›ã€‚ä¸å“Œç”²é…¯ç›¸æ¯”ï¼ŒIPPH æ›´å¼ºçš„æ•ˆåŠ›åœ¨å£æœç»™è¯æ—¶æœ€ä¸ºæ˜¾è‘—ï¼Œå› ä¸ºæ•ˆåŠ›çš„å·®å¼‚æ˜¯ç”±äº CES1 çš„è¾ƒä½äº²å’ŒåŠ›å¢åŠ äº† IPPH ç›¸è¾ƒäºå“Œç”²é…¯çš„ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œè€Œå“Œç”²é…¯ç”±äºè‚è„ä¸­ CES1 çš„é¦–è¿‡ä»£è°¢ï¼Œå£æœæ—¶çš„ç”Ÿç‰©åˆ©ç”¨åº¦æ˜æ˜¾è¾ƒä½ã€‚[\[5\]](#cite_note-MPHBioavailability-5)

å°½ç®¡è¿™ä¸¤ç§ç‰©è´¨ä¹‹é—´å­˜åœ¨æ˜¾ç€å·®å¼‚ï¼Œä½† IPPH ä»è¢«è®¤ä¸ºä¸»è¦ä½œä¸º[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine") [å†æ‘„å–æŠ‘åˆ¶å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")å‘æŒ¥ä½œç”¨ï¼Œè¿™æ„å‘³ç€å®ƒé€šè¿‡ç»“åˆå¹¶éƒ¨åˆ†é˜»æ–­é€šå¸¸ä»çªè§¦é—´éš™ç§»é™¤è¿™äº›å•èƒºçš„è½¬è¿è›‹ç™½ï¼Œä»è€Œæœ‰æ•ˆåœ°æé«˜å¤§è„‘ä¸­å»ç”²è‚¾ä¸Šè…ºç´ å’Œå¤šå·´èƒº[ç¥ç»é€’è´¨](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Neurotransmitters")çš„æ°´å¹³ã€‚è¿™ä½¿å¾—å¤šå·´èƒºå’Œå»ç”²è‚¾ä¸Šè…ºç´ åœ¨å¤§è„‘ä¸­ç§¯ç´¯ï¼Œä»è€Œäº§ç”Ÿåˆºæ¿€ä½œç”¨ã€‚

ä¸»è§‚æ•ˆåº”
------------------

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å‚è€ƒäº†[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](../æ–‡æ¡£/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](../å…³äºæœ¬ç«™/home.md "PsychonautWiki") [è´¡çŒ®è€…](../å…³äºæœ¬ç«™/home.md "Special:TopUsers")ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…å®ƒä»¬ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡æ›´é«˜å‰‚é‡æ›´å€¾å‘äºå¼•å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

* IPPH çš„èº¯ä½“æ•ˆåº”é€šå¸¸è¢«æè¿°ä¸ºæ¯”[ä¹™å“Œé†‹ç”²é…¯](../è¯ç‰©/EPH.md "Ethylphenidate")æ›´å°‘ä¸é€‚å’Œæ¬£å¿«ã€‚å®ƒä»¬å¯ä»¥åˆ†è§£ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œéšç€å‰‚é‡çš„å¢åŠ é€æ¸å¢å¼ºã€‚è¿™äº›æè¿°å¦‚ä¸‹ï¼Œé€šå¸¸åŒ…æ‹¬ï¼š


    + **[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")** \- IPPH é€šå¸¸è¢«è®¤ä¸ºå…·æœ‰ç²¾åŠ›å’Œåˆºæ¿€æ€§ï¼Œå…¶æ–¹å¼ç‹¬ç‰¹ä½†æ¯”[è‹¯ä¸™èƒº](../è¯ç‰©/è‹¯ä¸™èƒº.md "Amphetamine")æˆ–[ç”²åŸºè‹¯ä¸™èƒº](../è¯ç‰©/ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")å¼±å¾—å¤šï¼Œæ¯”[è«è¾¾è²å°¼](../è¯ç‰©/è«è¾¾è²å°¼.md "Modafinil")å’Œ[å’–å•¡å› ](../è¯ç‰©/å’–å•¡å› .md "Caffeine")å¼ºã€‚åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹ï¼Œå®ƒé¼“åŠ±ä¸€èˆ¬çš„ç”Ÿäº§åŠ›ï¼Œä½†åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒé¼“åŠ±èº«ä½“æ´»åŠ¨ï¼Œå¦‚è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ã€‚IPPH å‘ˆç°çš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºå¼ºè¿«æ€§çš„ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œéšç€ä¸‹é¢šç´§å’¬ã€ä¸è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’ŒæŒ¯åŠ¨å‡ºç°ï¼Œå˜å¾—éš¾ä»¥æˆ–ä¸å¯èƒ½ä¿æŒé™æ­¢ï¼Œå¯¼è‡´æ‰‹éƒ¨ä¸ç¨³ã€å…¨èº«é¢¤æŠ–å’Œè¿åŠ¨æ§åˆ¶çš„ä¸€èˆ¬ä¸§å¤±ã€‚
    + **[è„±æ°´](../è¯æ•ˆ/è„±æ°´.md "Dehydration")**
    + **[å£å¹²](../è¯æ•ˆ/å£å¹².md "Dry mouth")**
    + **[é£Ÿæ¬²æŠ‘åˆ¶](../è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md "Appetite suppression")**
    + **[è¡€ç®¡æ”¶ç¼©](../è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md "Vasoconstriction")**
    + **[å¿ƒç‡å¢å¿«](../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")**
    + **[å£è…”éº»æœ¨](../è¯æ•ˆ/å£è…”éº»æœ¨.md "Mouth numbing")** \- å½“[èˆŒä¸‹](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Sublingual")ç»™è¯æ—¶ï¼Œæ®æŠ¥é“ä¼šå‘ç”ŸæŒä¹…çš„éº»æœ¨æ„Ÿã€‚
    + **[ç£¨ç‰™](../è¯æ•ˆ/ç£¨ç‰™.md "Teeth grinding")** \- ä¸ [MDMA](../è¯ç‰©/MDMA.md "MDMA") ç›¸æ¯”ï¼Œè¿™ä¸€æˆåˆ†å¯è¢«è®¤ä¸ºè¾ƒä¸å¼ºçƒˆã€‚

### **è¯æ•ˆæ®‹ä½™**

* ä¸[è¯æ•ˆè¾¾å³°](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Peak")æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ç›¸æ¯”ï¼Œåœ¨[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä½“éªŒçš„[è¯æ•ˆè¤ªå»](../æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Offset")æœŸé—´å‘ç”Ÿçš„æ•ˆåº”é€šå¸¸æ„Ÿè§‰è´Ÿé¢å’Œä¸èˆ’æœã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œcomedownâ€ï¼Œæ˜¯å› ä¸º[ç¥ç»é€’è´¨](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Neurotransmitter")è€—ç«­æ‰€è‡´ã€‚å…¶æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š
    + **[ç„¦è™‘](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Anxiety")**
    + **[è®¤çŸ¥ç–²åŠ³](../è¯æ•ˆ/èº¯ä½“ç–²åŠ³.md "Cognitive fatigue")**
    + **[æŠ‘éƒ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Depression")**
    + **[æ˜“æ€’](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Irritability")**
    + **[åŠ¨æœºæŠ‘åˆ¶](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation suppression")**
    + **[æ€ç»´å‡é€Ÿ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought deceleration")**
    + **[æ¸…é†’](../è¯æ•ˆ/åˆºæ¿€.md "Wakefulness")**

### **è®¤çŸ¥æ•ˆåº”**

* IPPH çš„è®¤çŸ¥æ•ˆåº”å¯ä»¥åˆ†è§£ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œéšç€å‰‚é‡çš„å¢åŠ é€æ¸å¢å¼ºã€‚è®¸å¤šäººå°†å…¶ä¸€èˆ¬çš„ç²¾ç¥çŠ¶æ€æè¿°ä¸ºç²¾ç¥åˆºæ¿€ã€æ³¨æ„åŠ›é›†ä¸­å’Œå¯æ§çš„æ¬£å¿«æ„Ÿã€‚å®ƒåŒ…å«å¤§é‡å…¸å‹çš„[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")è®¤çŸ¥æ•ˆåº”ã€‚è™½ç„¶å‰¯ä½œç”¨åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹é€šå¸¸å¾ˆè½»å¾®ï¼Œä½†éšç€ç”¨é‡çš„å¢åŠ æˆ–é•¿æœŸä½¿ç”¨ï¼Œå®ƒä»¬å˜å¾—è¶Šæ¥è¶Šå¯èƒ½æ˜¾ç°å‡ºæ¥ã€‚è¿™åœ¨ä½“éªŒçš„è¯æ•ˆè¤ªå»æœŸé—´å°¤ä¸ºçœŸå®ã€‚

    è¿™äº›è®¤çŸ¥æ•ˆåº”ä¸­æœ€çªå‡ºçš„é€šå¸¸åŒ…æ‹¬ï¼š


    + **[åˆ†æèƒ½åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Analysis enhancement")**
    + **[ä¸“æ³¨åŠ›å¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Focus enhancement")** \- è¿™ä¸€æˆåˆ†åœ¨ä½è‡³ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸éƒ½ä¼šæŸå®³æ³¨æ„åŠ›ã€‚
    + **[åŠ¨æœºå¢å¼º](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Motivation enhancement")**
    + **[è€åŠ›å¢å¼º](../è¯æ•ˆ/è€åŠ›å¢å¼º.md "Stamina enhancement")**
    + **[æ€ç»´åŠ é€Ÿ](../è¯æ•ˆ/è§†è§‰åŠ å·¥åŠ é€Ÿ.md "Thought acceleration")**
    + **[æ€ç»´è¿é€šæ€§](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought connectivity")**
    + **[è®¤çŸ¥æ¬£å¿«](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive euphoria")** \- ä¸ IPPH ä½¿ç”¨ç›¸å…³çš„æ¬£å¿«å†²å‡»æ„Ÿï¼ˆä½œä¸º[å¤šå·´èƒº](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å†æ‘„å–æŠ‘åˆ¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Reuptake inhibition")çš„ç»“æœï¼‰éå¸¸çŸ­æš‚ä¸”å…·æœ‰å¼ºè¿«æ€§ï¼Œæ¨¡ç³Šåœ°ç±»ä¼¼äº[å¯å¡å› ](../è¯ç‰©/å¯å¡å› .md "Cocaine")ã€‚
    + **[éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º](../è¯æ•ˆ/å¬è§‰å¢å¼º.md "Increased music appreciation")**
    + **[æ€§æ¬²å¢å¼º](../è¯æ•ˆ/æ€§æ¬²å¢å¼º.md "Increased libido")** \- ä¸å…¶ä»–å…´å¥‹å‰‚ç›¸æ¯”ï¼Œè¿™ä¸€æˆåˆ†é€šå¸¸è¢«è®¤ä¸ºæ˜¯è½»å¾®çš„ã€‚
    + **[æ˜“æ€’](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Irritability")** \- åœ¨è¾ƒé«˜å‰‚é‡èŒƒå›´å†…ï¼Œè¿™é€šå¸¸åœ¨ä½“éªŒçš„é«˜å³°æœŸä»¥åŠè¯æ•ˆè¤ªå»æœŸé—´æ„Ÿè§‰åˆ°ã€‚è¿™å¯èƒ½å½’å› äºå®ƒè¡¨ç°å‡ºçš„ç›¸å¯¹äº[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Noradrenaline")æ´»æ€§è€Œè¨€å¼‚å¸¸é«˜çš„[å¤šå·´èƒºèƒ½](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")æ´»æ€§ã€‚[\[2\]](#cite_note-IPPH-2)
    + **[æ—¶é—´æ‰­æ›²](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")** \- è¿™å¯ä»¥æè¿°ä¸ºæ—¶é—´åŠ é€Ÿå’Œæµé€å¾—æ¯”æ¸…é†’æ—¶å¿«å¾—å¤šçš„ä½“éªŒã€‚
    + **[å¼ºè¿«æ€§è¡¥æœ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Compulsive redosing")** \- è¿™å¯ä»¥å½’å› äº IPPH å…·æœ‰çš„è½»åº¦è‡³ä¸­åº¦æ¬£å¿«å†²å‡»æ„Ÿå’Œç›¸å¯¹è¾ƒçŸ­çš„åŠè¡°æœŸï¼Œå½“é¼»å¸æ—¶å°¤ä¸ºçªå‡ºã€‚å»ºè®®é‚£äº›å¸Œæœ›å°†å…¶ç”¨äºç”Ÿäº§åŠ›ç›®çš„çš„äººä¸¥æ ¼é€šè¿‡[å£æœ](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of administration")ä»…æœç”¨ä½è‡³ä¸­ç­‰å‰‚é‡ã€‚[é¼»å¸](../æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of administration")ä¼šæ”¾å¤§è¡¥æœçš„å†²åŠ¨ã€‚è®¸å¤šç”¨æˆ·æŠ¥å‘Šè¯´ï¼ŒIPPH çš„å¼ºè¿«æ€§è¡¥æœæ–¹é¢æ¯”å¤§å¤šæ•°[ç ”ç©¶ç”¨åŒ–å­¦å“](../æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemical")å…´å¥‹å‰‚ï¼ˆå¦‚ [4F\-MPH](../è¯ç‰©/4F-MPH.md "4F-MPH")ã€[a\-PHP](../è¯ç‰©/Î±-PHP.md "A-PHP") æˆ– [Hexen](../è¯ç‰©/Hexen.md "Hexen")ï¼‰è¦æ¸©å’Œå’Œå¯æ§å¾—å¤šï¼Œè¿™å¯èƒ½æ˜¯ç”±äºç¼ºä¹æ˜æ˜¾çš„å†²å‡»æ„Ÿå’Œè¾ƒé•¿çš„è¯æ•ˆå‘ä½œæ—¶é—´ã€‚
    + **[æ¸…é†’](../è¯æ•ˆ/åˆºæ¿€.md "Wakefulness")**

### ä½“éªŒæŠ¥å‘Š

ç›®å‰çš„[ä½“éªŒç´¢å¼•](../æŠ¥å‘Š/psychounautwiki/ä½“éªŒç´¢å¼•.md "Experience index")ä¸­æœ‰æè¿°è¯¥åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘Šã€‚

* [ä½“éªŒ:30mg å“Œå¼‚ä¸™é…¯ \- IPPH ä½œä¸ºå­¦ä¹ è¾…åŠ©](../æŠ¥å‘Š/psychounautwiki/Experience:30mg_Isopropylphenidate_-_IPPH_As_A_Study_Aid.md "Experience:30mg Isopropylphenidate - IPPH As A Study Aid")
* [ä½“éªŒ:37mg å“Œå¼‚ä¸™é…¯ \- ç”¨å“Œå¼‚ä¸™é…¯æå®šäº‹æƒ…](../æŠ¥å‘Š/psychounautwiki/Experience:37mg_Isopropylphenidate_-_Getting_Shit_Done_With_Isopropylphenidate.md "Experience:37mg Isopropylphenidate - Getting Shit Done With Isopropylphenidate")


æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: Isopropylphenidate](https://erowid.org/experiences/subs/exp_Isopropylphenidate.shtml)


æ¯’æ€§å’Œå±å®³æ½œåŠ›
---------------------------

æ›´å¤šä¿¡æ¯ï¼š[ç ”ç©¶ç”¨åŒ–å­¦å“ Â§ æ¯’æ€§å’Œå±å®³æ½œåŠ›](../æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Research chemicals")

ä¼‘é—²æ€§ IPPH ä½¿ç”¨çš„æ¯’æ€§å’Œé•¿æœŸå¥åº·å½±å“ä¼¼ä¹å°šæœªåœ¨ä»»ä½•ç§‘å­¦èƒŒæ™¯ä¸‹è¿›è¡Œç ”ç©¶ï¼Œç¡®åˆ‡çš„æ¯’æ€§å‰‚é‡æœªçŸ¥ã€‚è¿™æ˜¯å› ä¸º IPPH çš„äººç±»ä½¿ç”¨å†å²å¾ˆå°‘ã€‚ç¤¾åŒºå†…å°è¯•è¿‡ IPPH çš„äººçš„è½¶äº‹è¯æ®è¡¨æ˜ï¼Œä»…ä»¥ä½è‡³ä¸­ç­‰å‰‚é‡å°è¯•è¿™ç§è¯ç‰©å¹¶å°‘é‡ä½¿ç”¨ä¼¼ä¹æ²¡æœ‰ä»»ä½•è´Ÿé¢å¥åº·å½±å“ï¼ˆä½†ä¸èƒ½å®Œå…¨ä¿è¯ä»»ä½•äº‹æƒ…ï¼‰ã€‚
å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¿™ç§è¯ç‰©æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚

### è€å—æ€§å’Œæˆç˜¾æ½œåŠ›

ä¸å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")ä¸€æ ·ï¼Œé•¿æœŸä½¿ç”¨ IPPH å¯è¢«è§†ä¸ºå…·æœ‰ä¸­ç­‰æˆç˜¾æ€§ï¼Œå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œå¹¶ä¸”èƒ½å¤Ÿå¯¼è‡´æŸäº›ä½¿ç”¨è€…äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚å½“æˆç˜¾å½¢æˆåï¼Œå¦‚æœä¸€ä¸ªäººçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ[æˆ’æ–­ååº”](../æ–‡æ¡£/è¯ç‰©æˆ’æ–­ååº”.md "Withdrawal effects")ã€‚

éšç€é•¿æœŸå’Œé‡å¤ä½¿ç”¨ï¼Œä¼šå¯¹ IPPH çš„è®¸å¤šæ•ˆåº”äº§ç”Ÿè€å—æ€§ã€‚è¿™å¯¼è‡´ä½¿ç”¨è€…å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆæœã€‚ä¹‹åï¼Œéœ€è¦å¤§çº¦ 3 \- 7 å¤©æ‰èƒ½å°†è€å—æ€§å‡å°‘åˆ°ä¸€åŠï¼Œéœ€è¦ 1 \- 2 å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨ä¸è¿›ä¸€æ­¥æ‘„å…¥çš„æƒ…å†µä¸‹ï¼‰ã€‚IPPH ä¸æ‰€æœ‰[å¤šå·´èƒºèƒ½](../æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine") [å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")è¡¨ç°å‡ºäº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æœç”¨ IPPH åï¼Œæ‰€æœ‰[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")çš„æ•ˆæœéƒ½ä¼šé™ä½ã€‚

### ç²¾ç¥ç—…

ä¸»æ¡ç›®ï¼š[å…´å¥‹å‰‚ç²¾ç¥ç—…](../æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Stimulant psychosis")

é•¿æœŸé«˜å‰‚é‡æ»¥ç”¨å…´å¥‹å‰‚ç±»åŒ–åˆç‰©å¯èƒ½å¯¼è‡´å…´å¥‹å‰‚ç²¾ç¥ç—…ï¼Œå¯èƒ½è¡¨ç°å‡ºå¤šç§ç—‡çŠ¶ï¼ˆä¾‹å¦‚ï¼Œ[åæ‰§](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Paranoia")ã€[å¹»è§‰](../è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "External hallucinations")æˆ–[å¦„æƒ³](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusions")ï¼‰ã€‚[\[6\]](#cite_note-stimpsychosis-6) ä¸€ç¯‡å…³äºè‹¯ä¸™èƒºã€[å³æ—‹è‹¯ä¸™èƒº](../è¯ç‰©/è‹¯ä¸™èƒº.md "Dextroamphetamine")å’Œ[ç”²åŸºè‹¯ä¸™èƒº](../è¯ç‰©/ç”²åŸºè‹¯ä¸™èƒº.md "Methamphetamine")æ»¥ç”¨è¯±å‘çš„ç²¾ç¥ç—…æ²»ç–—çš„ç»¼è¿°æŒ‡å‡ºï¼Œçº¦ 5â€“15% çš„ä½¿ç”¨è€…æœªèƒ½å®Œå…¨åº·å¤ã€‚[\[6\]](#cite_note-stimpsychosis-6)[\[7\]](#cite_note-7) åŒä¸€ç¯‡ç»¼è¿°æ–­è¨€ï¼ŒåŸºäºè‡³å°‘ä¸€é¡¹è¯•éªŒï¼Œ[æŠ—ç²¾ç¥ç—…](../è¯ç‰©/æŠ—ç²¾ç¥ç—…è¯.md "Antipsychotic")è¯ç‰©æœ‰æ•ˆåœ°è§£å†³äº†æ€¥æ€§è‹¯ä¸™èƒºç²¾ç¥ç—…çš„ç—‡çŠ¶ã€‚[\[6\]](#cite_note-stimpsychosis-6)

### å±é™©è¯ç‰©è”ç”¨

***è­¦å‘Šï¼š** è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å½“å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©è”ç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…å«æ‰€æœ‰ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚éƒ¨åˆ†åˆ—å‡ºçš„ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

* **[25x\-NBOMe](../è¯ç‰©/25x-NBOMe.md "25x-NBOMe") \& [25x\-NBOH](../è¯ç‰©/25x-NBOH.md "25x-NBOH")** \- 25x åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§å¹¶é€ æˆèº«ä½“å‹åŠ›ã€‚åº”ä¸¥æ ¼é¿å…ä¸ IPPH è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦[åˆºæ¿€](../è¯æ•ˆ/åˆºæ¿€.md "Stimulation")å’Œå¿ƒè„å‹åŠ›çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´[è¡€å‹å‡é«˜](../è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")ã€[è¡€ç®¡æ”¶ç¼©](../è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md "Vasoconstriction")ã€ææ…Œå‘ä½œã€[æ€ç»´å¾ªç¯](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought loops")ã€[ç™«ç—«å‘ä½œ](../è¯æ•ˆ/ç™«ç—«å‘ä½œ.md "Seizures")ï¼Œæç«¯æƒ…å†µä¸‹ç”šè‡³å¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
* **[é…’ç²¾](../è¯ç‰©/é…’ç²¾.md "Alcohol")** \- å°†é…’ç²¾ä¸[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ç»“åˆä½¿ç”¨å¯èƒ½å¾ˆå±é™©ï¼Œå› ä¸ºå­˜åœ¨æ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚æ©ç›–äº†é…’ç²¾çš„[æŠ‘åˆ¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨ï¼Œè€Œå¤§å¤šæ•°äººåˆ©ç”¨è¿™ç§ä½œç”¨æ¥è¯„ä¼°è‡ªå·±çš„ä¸­æ¯’ç¨‹åº¦ã€‚ä¸€æ—¦å…´å¥‹å‰‚å¤±æ•ˆï¼Œ[æŠ‘åˆ¶](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md "Depressant")ä½œç”¨å°†ä¸å—å¯¹æŠ—ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„[å‘¼å¸æŠ‘åˆ¶](../è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œä½¿ç”¨è€…åº”ä¸¥æ ¼é™åˆ¶æ¯å°æ—¶é¥®ç”¨çš„é…’ç²¾é‡ã€‚
* **[å³ç¾æ²™èŠ¬](../è¯ç‰©/å³ç¾æ²™èŠ¬.md "DXM")** \- åº”é¿å…ä¸ DXM è”ç”¨ï¼Œå› ä¸ºå®ƒå¯¹[è¡€æ¸…ç´ ](../æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")å’Œ[å»ç”²è‚¾ä¸Šè…ºç´ ](../æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Norepinephrine")å†æ‘„å–æœ‰æŠ‘åˆ¶ä½œç”¨ã€‚å­˜åœ¨[ææ…Œå‘ä½œ](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Panic attacks")å’Œé«˜è¡€å‹å±è±¡çš„é£é™©å¢åŠ ï¼Œæˆ–ä¸è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼ˆ[MDMA](../è¯ç‰©/MDMA.md "MDMA")ã€[ç”²é…®](../è¯ç‰©/ç”²é…®.md "Methylone")ã€[ç”²å¡è¥¿é…®](../è¯ç‰©/ç”²å¡è¥¿é…®.md "Mephedrone")ç­‰ï¼‰è”ç”¨æ—¶å‡ºç°[è¡€æ¸…ç´ ç»¼åˆå¾](../æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ã€‚ä»”ç»†ç›‘æµ‹è¡€å‹å¹¶é¿å…å‰§çƒˆè¿åŠ¨ã€‚
* **[MDMA](../è¯ç‰©/MDMA.md "MDMA")** \- å½“å­˜åœ¨å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§ä½œç”¨éƒ½å¯èƒ½å¢åŠ ã€‚è¿˜å­˜åœ¨è¡€å‹è¿‡é«˜å’Œå¿ƒè„å‹åŠ›ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
* **[MXE](../è¯ç‰©/MXE.md "MXE")** \- ä¸€äº›æŠ¥å‘Šè¡¨æ˜ä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹å¹¶å¢åŠ [èºç‹‚](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](../æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Psychosis")çš„é£é™©ã€‚
* **[è§£ç¦»å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md "Dissociatives")** \- è¿™ä¸¤ç±»è¯ç‰©éƒ½å¸¦æœ‰[å¦„æƒ³](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusions")ã€[èºç‹‚](../è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mania")å’Œ[ç²¾ç¥ç—…](../æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Psychosis")çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™äº›é£é™©å¯èƒ½ä¼šæˆå€å¢åŠ ã€‚
* **[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")** \- IPPH ä¸å…¶ä»–[å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")å¦‚[å¯å¡å› ](../è¯ç‰©/å¯å¡å› .md "Cocaine")è”ç”¨å¯èƒ½å¾ˆå±é™©ï¼Œå› ä¸ºå®ƒä»¬ä¼š[å¢åŠ å¿ƒç‡](../è¯æ•ˆ/å¿ƒç‡å¢å¿«.md "Increased heart rate")å’Œ[è¡€å‹](../è¯æ•ˆ/è¡€å‹å‡é«˜.md "Increased blood pressure")è‡³å±é™©æ°´å¹³ã€‚
* **[æ›²é©¬å¤š](../è¯ç‰©/æ›²é©¬å¤š.md "Tramadol")** \- å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«é˜ˆå€¼[\[8\]](#cite_note-8)ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚


* **[MAOIs](../è¯ç‰©/MAOIs.md "MAOIs")** \- è¿™ç§ç»„åˆå¯èƒ½ä¼šå°†å¤šå·´èƒºç­‰ç¥ç»é€’è´¨çš„æ•°é‡å¢åŠ åˆ°å±é™©ç”šè‡³è‡´å‘½çš„æ°´å¹³ã€‚ä¾‹å¦‚[éª†é©¼è“¬å­](../è¯ç‰©/éª†é©¼è“¬å­.md "Syrian rue")ã€[*Banisteriopsis caapi*](../è¯ç‰©/Banisteriopsis_caapi.md "Banisteriopsis caapi") å’Œä¸€äº›[æŠ—æŠ‘éƒè¯](../è¯ç‰©/æŠ—æŠ‘éƒè¯.md "Antidepressants")ã€‚[\[9\]](#cite_note-9)


æ³•å¾‹åœ°ä½
------------

| [![Handcuffs-300px.png](../æ–‡ä»¶/Handcuffs-300px.png)](../æ–‡ä»¶/Handcuffs-300px.png) | **æœ¬æ³•å¾‹éƒ¨åˆ†æ˜¯ä¸€ä¸ª[å°èŠ‚](../å…³äºæœ¬ç«™/home.md "Stub")ã€‚**<br>*å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚æ‚¨å¯ä»¥é€šè¿‡[æ‰©å±•å®ƒ](https://psychonautwiki.org/w/index.php?title=Isopropylphenidate&action=edit)æ¥æä¾›å¸®åŠ©ã€‚* |
| --- | --- |

* **å¾·å›½**ï¼šæˆªè‡³ 2016 å¹´ 11 æœˆ 26 æ—¥ï¼ŒIPPH å— NpSGï¼ˆ*æ–°ç²¾ç¥æ´»æ€§ç‰©è´¨æ³•*ï¼‰ç®¡åˆ¶ã€‚[\[10\]](#cite_note-10)[\[11\]](#cite_note-11) ä»¥å°†å…¶æŠ•æ”¾å¸‚åœºä¸ºç›®çš„çš„ç”Ÿäº§å’Œè¿›å£ã€å¯¹ä»–äººçš„ç®¡ç†å’Œäº¤æ˜“å‡å—åˆ°æƒ©ç½šã€‚æ‹¥æœ‰æ˜¯éæ³•çš„ï¼Œä½†ä¸äºˆå¤„ç½šã€‚[\[12\]](#cite_note-12)
* **ç‘å£«**ï¼šIPPH æ˜¯ Verzeichnis E ä¸‹ç‰¹åˆ«åˆ—å‡ºçš„ç®¡åˆ¶ç‰©è´¨ã€‚[\[13\]](#cite_note-13)
* **åœŸè€³å…¶**ï¼šæˆªè‡³ 2016 å¹´ 2 æœˆï¼ŒIPPH åœ¨åœŸè€³å…¶æ˜¯éæ³•çš„ã€‚[\[14\]](#cite_note-14)
* **è‹±å›½**ï¼šæˆªè‡³ 2017 å¹´ 5 æœˆ 31 æ—¥ï¼ŒIPPH åœ¨è‹±å›½å±äº B ç±»è¯ç‰©ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§æˆ–ä¾›åº”å‡å±éæ³•ã€‚[\[15\]](#cite_note-15)
* **åŠ æ‹¿å¤§**ï¼šIPPH åœ¨åŠ æ‹¿å¤§æ˜¯é™„è¡¨ III è¯ç‰©ã€‚[\[16\]](#cite_note-16)


å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](../æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")
* [ç­–åˆ’è¯](../æ–‡æ¡£/ç ”ç©¶ç”¨åŒ–å­¦å“.md "Designer drug")
* [å…´å¥‹å‰‚](../æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")
* [å“Œç”²é…¯](../è¯ç‰©/å“Œç”²é…¯.md "Methylphenidate")
* [ä¹™å“Œé†‹ç”²é…¯](../è¯ç‰©/EPH.md "Ethylphenidate")


å¤–éƒ¨é“¾æ¥
--------------

* [Isopropylphenidate (Wikipedia)](https://en.wikipedia.org/wiki/Isopropylphenidate)
* [Isopropylphenidate (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=635)


æ–‡çŒ®
----------

* Markowitz, J. S., Zhu, H., \& Patrick, K. S. (2013\). Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability. Journal of Child and Adolescent Psychopharmacology, 23(10\), 648\-654\. <https://doi.org/10.1089/cap.2013.0074>
* John S. Markowitz; Kennerly S. Patrick; Haojie Zhu (Sep 27, 2012\). "Patent US20120245201 \- Isopropylphenidate for Treatment of Attention\-Deficit/Hyperactivity Disorder and Fatigue\-Related Disorders and Conditions". Retrieved 15 August 2014\.


å‚è€ƒèµ„æ–™
----------

1. â†‘ [1\.0](#cite_ref-IPPHadhd_1-0) [1\.1](#cite_ref-IPPHadhd_1-1) Markowitz, J. S., Patrick, K. S., Zhu, H., [*Isopropylphenidate for Treatment of Attention\-Deficit/Hyperactivity Disorder and Fatigue\-Related Disorders and Conditions*](https://patents.google.com/patent/US20120245201A1/en)Â 
2. â†‘ [2\.0](#cite_ref-IPPH_2-0) [2\.1](#cite_ref-IPPH_2-1) [2\.2](#cite_ref-IPPH_2-2) [2\.3](#cite_ref-IPPH_2-3) Markowitz, J. S., Zhu, H.\-J., Patrick, K. S. (December 2013\). ["Isopropylphenidate: An Ester Homolog of Methylphenidate with Sustained and Selective Dopaminergic Activity and Reduced Drug Interaction Liability"](http://www.liebertpub.com/doi/10.1089/cap.2013.0074). *Journal of Child and Adolescent Psychopharmacology*. **23** (10\): 648â€“654\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1089/cap.2013\.0074](//doi.org/10.1089%2Fcap.2013.0074). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1044\-5463](//www.worldcat.org/issn/1044-5463).Â 
3. [â†‘](#cite_ref-IPPHSynthesis_3-0) Leon, L., Louis, M., [*Therapeutic lower alkyl esters of alpha\-phenyl\-alpha\-piperidyl\-(2\)\-acetic acid*](https://patents.google.com/patent/US3060089A/en)Â 
4. [â†‘](#cite_ref-PhenidateHydrolysis_4-0) Portoghese, P. S., Malspeis, L. (June 1961\). ["Relative Hydrolytic Rates of Certain Alkyl (b) dl\-Î±\-(2\-Piperidyl)\-phenylacetates"](https://linkinghub.elsevier.com/retrieve/pii/S0022354915331865). *Journal of Pharmaceutical Sciences*. **50** (6\): 494â€“501\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1002/jps.2600500611](//doi.org/10.1002%2Fjps.2600500611). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0022\-3549](//www.worldcat.org/issn/0022-3549).Â 
5. [â†‘](#cite_ref-MPHBioavailability_5-0) Kimko, H. C., Cross, J. T., Abernethy, D. R. (1999\). ["Pharmacokinetics and Clinical Effectiveness of Methylphenidate:"](http://link.springer.com/10.2165/00003088-199937060-00002). *Clinical Pharmacokinetics*. **37** (6\): 457â€“470\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.2165/00003088\-199937060\-00002](//doi.org/10.2165%2F00003088-199937060-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0312\-5963](//www.worldcat.org/issn/0312-5963).Â 
6. â†‘ [6\.0](#cite_ref-stimpsychosis_6-0) [6\.1](#cite_ref-stimpsychosis_6-1) [6\.2](#cite_ref-stimpsychosis_6-2) Shoptaw, S. J., Kao, U., Ling, W. (21 January 2009\). Cochrane Drugs and Alcohol Group, ed. ["Treatment for amphetamine psychosis"](https://doi.wiley.com/10.1002/14651858.CD003026.pub3). *Cochrane Database of Systematic Reviews*. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1002/14651858\.CD003026\.pub3](//doi.org/10.1002%2F14651858.CD003026.pub3). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1465\-1858](//www.worldcat.org/issn/1465-1858).Â 
7. [â†‘](#cite_ref-7) Hofmann, F. G. (1983\). *A handbook on drug and alcohol abuse: the biomedical aspects* (2nd ed ed.). Oxford University Press. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number")Â [9780195030563](http://en.wikipedia.org/wiki/Special:BookSources/9780195030563 "wikipedia:Special:BookSources/9780195030563").Â CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
8. [â†‘](#cite_ref-8) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009\). "Dose\-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2\): 63â€“67\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1937\-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1556\-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [163567183](//www.worldcat.org/oclc/163567183).Â 
9. [â†‘](#cite_ref-9) Gillman, P. K. (2005\). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4\): 434â€“441\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number")Â [1471\-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0007\-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC")Â [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier")Â [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).Â 
10. [â†‘](#cite_ref-10) ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 24, 2019.Â 
11. [â†‘](#cite_ref-11) ["Gesetz zur BekÃ¤mpfung der Verbreitung neuer psychoaktiver Stoffe"](https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518) (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 24, 2019.Â 
12. [â†‘](#cite_ref-12) ["Â§ 4 NpSG"](https://www.gesetze-im-internet.de/npsg/__4.html) (in German). Bundesministerium der Justiz und fÃ¼r Verbraucherschutz. Retrieved December 24, 2019.Â 
13. [â†‘](#cite_ref-13) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei \[Federal Chancellery of Switzerland\]. Retrieved January 1, 2020.Â 
14. [â†‘](#cite_ref-14) ["Karar SayÄ±sÄ± : 2016/8548"](https://www.resmigazete.gov.tr/eskiler/2016/03/20160308-4.pdf) (PDF) (in Turkish). Resmi Gazete. Retrieved January 15, 2020.Â 
15. [â†‘](#cite_ref-15) [*The Misuse of Drugs Act 1971 (Amendment) Order 2017*](https://www.legislation.gov.uk/uksi/2017/634/made)Â 
16. [â†‘](#cite_ref-16) ["Controlled Drugs and Substances Act"](https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-15.html) (in English). Retrieved April 8, 2021.